Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FAB-3511
- Development stage
- Unknown
- Lead developer
- Fluart Innovative Vaccines
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**FAB-3511** is an investigational trivalent seasonal influenza vaccine developed by Fluart Innovative Vaccines. In the completed randomized, double-blind NCT01408290 dose-ranging study, it was the 3.5 microgram hemagglutinin dose formulation administered as a single 0.5 mL intramuscular injection and contained seasonal influenza A/H1N1, influenza A/H3N2, and influenza B antigens. It is intended to induce protective active immunity against seasonal influenza. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01408290))
- Other names
- FAB 3511FAB3511FAB-3511
Beyond the preview
Go deeper on FAB-3511.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FAB-3511.